| Design of therapeutic proteins with enhanced stability N Chennamsetty, V Voynov, V Kayser, B Helk, BL Trout Proceedings of the National Academy of Sciences 106 (29), 11937-11942, 2009 | 632 | 2009 |
| The state-of-play and future of antibody therapeutics Z Elgundi, M Reslan, E Cruz, V Sifniotis, V Kayser Advanced drug delivery reviews 122, 2-19, 2017 | 325 | 2017 |
| Prediction of aggregation prone regions of therapeutic proteins N Chennamsetty, V Voynov, V Kayser, B Helk, BL Trout The Journal of Physical Chemistry B 114 (19), 6614-6624, 2010 | 202 | 2010 |
| Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy E Cruz, V Kayser Biologics: targets and therapy, 33-51, 2019 | 198 | 2019 |
| Aggregation-prone motifs in human immunoglobulin G N Chennamsetty, B Helk, V Voynov, V Kayser, BL Trout Journal of molecular biology 391 (2), 404-413, 2009 | 180 | 2009 |
| Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies V Kayser, N Chennamsetty, V Voynov, K Forrer, B Helk, BL Trout Biotechnology journal 6 (1), 38-44, 2011 | 176 | 2011 |
| Ionic liquids as biocompatible stabilizers of proteins M Reslan, V Kayser Biophysical reviews 10, 781-793, 2018 | 108 | 2018 |
| Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation V Kayser, N Chennamsetty, V Voynov, B Helk, K Forrer, BL Trout Journal of pharmaceutical sciences 100 (7), 2526-2542, 2011 | 104 | 2011 |
| Femtosecond electron-transfer reactions in mono-and polynucleotides and in DNA GD Reid, DJ Whittaker, MA Day, DA Turton, V Kayser, JM Kelly, ... Journal of the American Chemical Society 124 (19), 5518-5527, 2002 | 95 | 2002 |
| Vaccines and vaccination: history and emerging issues V Kayser, I Ramzan Human vaccines & immunotherapeutics 17 (12), 5255-5268, 2021 | 90 | 2021 |
| Vaccine hesitancy: contemporary issues and historical background RF Nuwarda, I Ramzan, L Weekes, V Kayser Vaccines 10 (10), 1595, 2022 | 83 | 2022 |
| Advances and limitations of antibody drug conjugates for cancer CM Mckertish, V Kayser Biomedicines 9 (8), 872, 2021 | 83 | 2021 |
| An overview of influenza viruses and vaccines RF Nuwarda, AA Alharbi, V Kayser Vaccines 9 (9), 1032, 2021 | 80 | 2021 |
| Current advancements in addressing key challenges of therapeutic antibody design, manufacture, and formulation V Sifniotis, E Cruz, B Eroglu, V Kayser Antibodies 8 (2), 36, 2019 | 74 | 2019 |
| Predictive tools for stabilization of therapeutic proteins V Voynov, N Chennamsetty, V Kayser, B Helk, BL Trout MAbs 1 (6), 580-582, 2009 | 73 | 2009 |
| New compounds based on a benzimidazole nucleus: synthesis, characterization and cytotoxic activity against breast and colon cancer cell lines S Akkoç, V Kayser, İÖ İlhan, DE Hibbs, Y Gök, PA Williams, B Hawkins, ... Journal of Organometallic Chemistry 839, 98-107, 2017 | 70 | 2017 |
| Poly (methyl vinyl ether-co-maleic acid)–Pectin based hydrogel-forming systems: Gel, film, and microneedles YK Demir, AÜ Metin, B Şatıroğlu, ME Solmaz, V Kayser, K Mäder European Journal of Pharmaceutics and Biopharmaceutics 117, 182-194, 2017 | 64 | 2017 |
| A narrative review of COVID-19 vaccines B Eroglu, RF Nuwarda, I Ramzan, V Kayser Vaccines 10 (1), 62, 2021 | 60 | 2021 |
| Design and application of antibody cysteine variants V Voynov, N Chennamsetty, V Kayser, HJ Wallny, B Helk, BL Trout Bioconjugate chemistry 21 (2), 385-392, 2010 | 60 | 2010 |
| Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation V Voynov, N Chennamsetty, V Kayser, B Helk, K Forrer, H Zhang, ... PLoS One 4 (12), e8425, 2009 | 57 | 2009 |
Associate Professor Senem AkkocSuleyman Demirel University在 sdu.edu.tr 的电子邮件经过验证
